Drug profile

The FDA adverse-event record for Pyrimethamine + Sulfadiazine

23 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Pyrimethamine + Sulfadiazine. See the species affected, top reactions, and outcomes below.

23
adverse-event reports
13.0%
death-coded share
Horse
most-reported species
4
Lethargy (see also Central nervous system depression in 'Neurological') - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
23
Total Reports
3
Deaths Reported
13.0%
Death Rate

Active Ingredients

PyrimethamineSulfadiazine

Administration Routes

OralUnknown

Species Affected

Horse 20
Unknown 3

Most Affected Breeds

Quarter Horse 6
Unknown 5
Thoroughbred 3
Standardbred (unspecified) 2
Mixed (Horse) 2
Pura Raza Española (Andalusian) 1
Warmblood (unspecified) 1
Missouri Fox Trotting Horse 1
Rocky Mountain Horse 1
Horse (other) 1

Most Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 4
Potency, Low 3
Leucopenia NOS 3
Diarrhoea 3
Decreased appetite 3
Death by euthanasia 2
Restlessness 2
Lack of efficacy - NOS 2
Lack of efficacy (protozoa) - NOS 2
Product problem 2
Neurological signs NOS 2
Ataxia 2

Outcome Breakdown

Outcome Unknown
9 (45.0%)
Recovered/Normal
6 (30.0%)
Euthanized
2 (10.0%)
Ongoing
2 (10.0%)
Died
1 (5.0%)

Pyrimethamine + Sulfadiazine Adverse Event Insights

23 reports name Pyrimethamine + Sulfadiazine; 3 recorded a death outcome (13.0% of reported events, not a population-level mortality rate). Active ingredients: Pyrimethamine, Sulfadiazine. Administration routes: Oral, Unknown.

By species: Horse (20 reports), Unknown (3 reports). By breed: Quarter Horse (6), Unknown (5), Thoroughbred (3).

Leading clinical signs: Lethargy (see also Central nervous system depression in 'Neurological') (4), Potency, Low (3), Leucopenia NOS (3), Diarrhoea (3). Outcome, 20 coded reports: Outcome Unknown leads at 45.0%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.